Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues

Definitions

• the present invention relates to a method for efficiently producing adhesive cells such as mesenchymal stem cells from tissues.
• Adhesive mesenchymal stem cells are somatic stem cells that have been reported to be present in bone marrow, adipose tissue, dental pulp, etc., and have the ability to differentiate into bone, cartilage, fat, etc., and are therefore promising in cell therapy. It is attracting attention as a cell source.
• Mesenchymal stem cells have not only differentiation ability but also immunosuppressive ability, and clinical application for acute graft-versus-host disease (GVHD) and Crohn's disease is advancing.
• GVHD graft-versus-host disease
• skeletal myoblasts separated from muscle tissue are also known to have adhesiveness and secrete cytokines that promote tissue regeneration, and have been put into practical use as myocardial regeneration therapy by Telmo.
• fibroblasts that can be separated from skin tissue also have adhesiveness and are used in clinical practice for anti-aging such as cosmetology.
• An object of the present invention is to provide a method for safely storing and / or transporting a raw material tissue containing adhesive cells such as mesenchymal stem cells, and to efficiently obtain adhesive cells from the raw material tissue containing the adhesive cells after storage / transportation. Is to provide a method of manufacturing.
• the tissue was immersed in a buffer solution or an organ preservation solution, preserved and / or transported, and an attempt was made to produce adhesive cells from the tissue.
• the tissue was preserved and / or transported. It was confirmed that the cells were damaged and induced a decrease in adhesiveness and damage to the adhesive cells in the tissue, and therefore the number of acquired cells decreased.
• the present inventors surprisingly suppressed the damage to the tissue by storing and / or transporting the tissue in a medium having an appropriate compressive stress. It was found that the adhesive cells could be efficiently produced.
• a method for producing a cell population containing the cells from a tissue containing the adhesive cells Tissues containing adherent cells are stored and / or transported embedded in a medium with a compressive stress greater than 0 and 12 N or less.
• a method for producing adhesive cells from a tissue which comprises removing the tissue embedded in the medium from the medium and separating the adhesive cells.
• tissues containing adherent cells such as mesenchymal stem cells can be safely preserved / transported, and adherent cells can be efficiently produced after storage / transport.
• adhesive cells refer to cells that adhere to a petri dish, plate, or flask of a glass or plastic substrate and exhibit a spindle-shaped morphology.
• adhesive cells include mesenchymal stem cells, skeletal myoblasts, fibroblasts, epithelial cells, myocardial stem cells, nerve stem cells, hepatic stem cells, myocardial cells, nerve cells, hepatocytes, etc. Is not limited to these cells.
• Tissues containing adhesive cells include solid tissues such as fat, placenta, fetal membrane, amniotic membrane, villous membrane, skin, umbilical cord, heart, brain, lung, corneal membrane, intestine, muscle, and synovial cord, bone marrow, dental pulp, sheep's water, and umbilical cord.
• solid tissues such as fat, placenta, fetal membrane, amniotic membrane, villous membrane, skin, umbilical cord, heart, brain, lung, corneal membrane, intestine, muscle, and synovial cord, bone marrow, dental pulp, sheep's water, and umbilical cord.
• liquid tissues such as blood and blood, but the present invention is not limited to these tissues. In addition, those obtained by processing these structures are also included.
• the "medium” in the present invention may have any state, properties, and structure as long as the compressive stress is greater than 0 and 12 N or less.
• it may have any properties such as solid, liquid, and gas, and may be in a mixed state.
• Specific examples of the medium having a compressive stress greater than 0 and 12 N or less include gels, sol, and the like. Something similar to.
• the gel refers to a gel in which colloidal particles are dispersed in a liquid or a gas and lose their fluidity, and examples thereof include konjac, yokan, agar, and pudding.
• the sol refers to a sol in which colloidal particles are dispersed in a liquid or a gas and the fluidity is not lost, and examples thereof include milk, yogurt to drink, and oil.
• a colloid using water as a dispersion medium is preferable, and a so-called hydrogel is more preferable.
• the medium of the present invention preferably has an appropriate hardness, and as described above, compressive stress is adopted as an index of the hardness.
• a method for measuring compressive stress in the present invention a 2 mL medium is placed in a 24-well plate, the medium is compressed with a plunger having a diameter of 1 cm, and the stress (unit: N) when the medium is compressed by 1.5 mm is EZ. -It is obtained by measuring with TEST (Shimadzu Corporation, EZ-SX), but it is not limited to the above method when the same result can be obtained.
• the compressive stress of the medium must satisfy the above range of "greater than 0 and 12 N or less" at the temperature during storage and / or transportation.
• compressive stress at 4 ° C. for storage and transport at 4 ° C. and compressive stress at 15 ° C. for storage and transport at 15 ° C.
• the compressive stress is not particularly limited as long as it is greater than 0 and 12 N or less, but is preferably 0.001 N or more, more preferably 0.005 N or more, further preferably 0.01 N or more, and most preferably 0.1 N or more.
• the compressive stress is preferably 11 N or less, more preferably 10 N or less, and even more preferably 9 N or less. 8N or less is more preferable, and 7N or less is most preferable.
• any one of the temperatures may be within the above compressive stress range, but at least 40% of the entire storage and / or transportation process.
• the above period preferably satisfies the above compressive stress, more preferably 60% or more, further preferably 80% or more, and most preferably satisfying the above compressive stress under all temperature conditions. For example, when stored once at 4 ° C and transported in the range of 15 ° C to 25 ° C, any one of the compressive stresses at 4 ° C and 15 ° C to 25 ° C falls within the above compressive stress range. However, it is more preferable to satisfy all of them.
• the medium described in the present invention preferably contains at least one selected from the group consisting of proteins, peptides, polysaccharides and synthetic polymers, and in the present invention, these are dispersed in water. It is more preferable to use a medium as a medium, but the present invention is not limited thereto.
• a medium As the protein, gelatin, collagen, fibrin, soybean protein and the like can be used.
• Polysaccharides or substances containing polysaccharides include agarose, pectin, carrageenan, curdlan, chitin, chitosan, arginic acids, soybean polysaccharides, celluloses such as carboxymethyl cellulose, mannans, arabic gum, gellan gum, guar gum, xanthan gum, starch, agar. , Fucoidan, etc. can be used.
• synthetic polymer synthetic peptides (self-assembled peptides such as Panacea gel and PuraMatrix), polyvinyl alcohol, propylene glycol, silicon, polyacrylamide and the like can be used. Further, these may be used alone or in combination of two or more.
• culture solution in the present specification is not particularly limited, and any liquid medium for cell culture is used as a basal medium, and other components (albumin, blood-derived components, growth factors, etc.) are appropriately added as needed. Can be prepared by.
• BME medium BME medium, BGJb medium, CMRL1066 medium, Glasgo MEM medium, Applied MEM Zinc Option medium, IMDM medium (Iscover's Modified Dulvecco's Medium), Medium 199 Medium, Eagle's Medium, Eagle's Medium, Eagle's Medium, Eagle's Medium, Eagle's Medium, Eagle's Medium of Medium Essential Medium Eagle's medium, DMEM medium (Dulvecco's Modified Eagle's Medium), ham F10 medium, ham F12 medium, RPMI 1640 medium, Fisher's medium, and a mixed medium thereof (for example, DMEM / F12 medium). (Dulvecco's Modified Eagle's Medium / Nutient Mixture F-12 Ham)) and the like can be used, but the medium is not particularly limited. In addition, various commercially available serum-free media can also be used.
• albumin examples include albumin, blood-derived components, growth factors, and the like.
• concentration of albumin is preferably 0.05% by weight or more and 5% by weight or less.
• various sera animal-derived serum such as bovine fetal serum (FBS or FCS), human serum, various animal and / or human blood-derived multiplatelet plasma and platelet lysate are prepared as raw materials. Serum, etc.), various animal and / or human blood-derived platelet lysates, plasma, etc.
• the human serum may be derived from the same individual as the individual from which the tissue containing the adhesive cells was obtained, or may be derived from a different individual.
• the concentration of the blood-derived component is preferably 2% by volume or more and 40% or less by volume. More preferably, it is 3% by volume or more and 30% or less by volume.
• a reagent for stabilizing the growth factor in the medium antioxidant such as heparin, gel, polysaccharide, etc.
• Pre-stabilized growth factors may be added to the basal medium.
• Growth factors include, for example, fibroblast growth factor (FGF), epithelial cell growth factor (EGF), transforming growth factor (TGF), vascular endothelial cell growth factor (VEGF), platelet-derived growth factor (PDGF), and theirs. Families can be used, but are not particularly limited.
• FGF fibroblast growth factor
• EGF epithelial cell growth factor
• TGF transforming growth factor
• VEGF vascular endothelial cell growth factor
• PDGF platelet-derived growth factor
• the step of collecting tissue containing adherent cells such as mesenchymal stem cells can be performed by, for example, the following procedure. can.
• adipose tissue make an incision of about 0.5 cm to 1 cm in any part of the patient (for example, abdomen, waist, tweezers) with a sharp-edged scalpel, and use any surgical instrument (for example, mosquito forceps, tweezers) to make fat. Is removed and excised. The incision should be sutured with one needle or taped.
• Adipose tissue collected by such means is generally called excised fat.
• fat can be aspirated from any part of the patient (for example, abdomen, waist, thigh) using a cannula or the like.
• Adipose tissue collected by such means is generally called aspirated fat.
• amniotic tissue fetal appendages (placenta, fetal membrane, etc.) are collected at birth, and then the amniotic membrane is detached from the stump of the fetal membrane.
• muscular tissue the muscular tissue is collected from the thigh.
• skin tissue it may be collected from the back of the ear using a surgical disposable knife, a skin biopsy punch, or the like, but the present invention is not limited thereto.
• the collected tissue is stored and / or transported in a state of being embedded in a medium, and can be carried out by the following procedure, for example.
• the tissue is embedded, stored and / or transported by embedding the collected tissue in a container-filled medium or by adding the medium to the container containing the collected tissue.
• the step of taking out the tissue embedded in the medium can be performed, for example, by the following procedure.
• the tissue is removed from the medium in which the tissue is embedded using any instrument (eg, mosquito forceps, tweezers, etc.).
• the tissue is preferably preserved / transported as follows by utilizing the property. be able to.
• gelatin is used as an example, gelatin is dissolved or dispersed in a dispersion medium such as an aqueous solution as described below to prepare a gelatin solution, and then the gelatin solution is heated to liquefy and the collected tissue is embedded.
• the gelatin solution in which the tissue is embedded can be cooled to solidify and stored and / or transported in a gel-embedded state. Then, by heating, the gelatin solution can be liquefied and the embedded tissue can be taken out.
• the temperature at which the above gelatin solution is liquefied varies depending on the gelatin concentration, and is, for example, 25 ° C. or higher and 60 ° C. or lower. Is more preferable.
• the temperature at which the gelatin solution is solidified varies depending on the gelatin concentration, but is more preferably 1 ° C. or higher and 25 ° C. or lower, and 1 ° C. or higher and 10 ° C. or lower.
• Gelatin is extracted from pig skin, pork bones, fish, cows, humans, etc., but gelatin extracted from any animal can be used. Further, it may be hydrolyzed with an acid or an alkali, but the type of gelatin is not limited in the present invention.
• the dispersion medium for dissolving gelatin can be any water or an aqueous solution
• the aqueous solution can be any aqueous solution such as a buffer solution, an isotonic solution, a hypotonic solution, and a hypertonic solution. ..
• buffers and isotonic solutions are more preferable, for example, PBS, HBSS (-), Ringer's solution, Ringer's lactate, infusion solution, saline solution, culture solution, albumin solution, blood-derived components, and the like. Examples include a mixture of.
• an antibiotic may be added to the above medium.
• the storage and transportation time is not particularly limited, but it is preferably within 10 days from the viewpoint of reducing damage to the tissue. More specifically, 9 days or less, 8 days or less, 7 days or less, 6 days or less, 5 days or less, 4 days or less, 3 days or less, 2 days or less and 1 day or less can be mentioned.
• the lower limit of the storage and transportation time is not particularly limited, but is, for example, 30 minutes or more, 1 hour or more, 2 hours or more, 3 hours or more, 4 hours or more, 5 hours or more, and 6 hours or more.
• the storage and transportation temperatures are not particularly limited, but 37 ° C or lower is preferable from the viewpoint of reducing damage to tissues. More specifically, it is 30 ° C. or lower, 25 ° C. or lower, 20 ° C. or lower, 15 ° C. or lower, 10 ° C. or lower, or 5 ° C. or lower.
• the lower limit of the storage and transportation temperature is not particularly limited, but is, for example, ⁇ 5 ° C. or higher and 0 ° C. or higher.
• the step of separating the adhesive cells from the tissue taken out from the medium can be performed by, for example, the following procedure.
• the removed tissue is treated with an enzyme, then the adherent cells are separated by centrifugation, and washing and centrifugation are repeated multiple times with a washing solution.
• a washing solution in order to improve the digestibility by the enzyme, it may be cut into small pieces with scissors before the enzyme treatment.
• the enzyme treatment solution collagenase, dispase and the like can be used, but the present invention is not limited thereto.
• [3] Method for Producing Cell Population Containing Adhesive Cells Separated from Tissue Containing Adhesive Cells are, for example, as follows. It can be done by the procedure like. First, the cell suspension is centrifuged, the supernatant is removed, and the obtained cell pellet is suspended in a medium. Next, the cells are seeded in a culture vessel and cultured in a medium with a CO 2 concentration of 3% or more and 5% or less and a confluence rate of 95% or less.
• the “culture solution” described in the explanation of the term [1] can be used, but the present invention is not limited thereto.
• a method for producing the tissue without enzymatic treatment can be applied, for example, ceiling culture (property of floating on water). Tissue pieces are floated when the amount of medium is large. Therefore, the liquid amount can be manufactured by a method of minimizing the amount of the tissue to be immersed, a method of adhering the tissue to the dish by suppressing the floating of the tissue piece by a mesh, etc.), but the present invention is not limited to these.
• the cells obtained by the above-mentioned culture are cells that have been cultured once (cells of the 0th passage).
• the culture period of the above-mentioned single culture can be, for example, 2 to 21 days, more preferably 3 to 19 days, and further preferably 4 to 17 days.
• the above-mentioned single-cultured cells can be further subcultured and cultured as follows, for example. First, the cells once cultured are treated with a cell exfoliation means such as trypsin and exfoliated from the culture vessel. The resulting cell suspension is then centrifuged, the supernatant is removed, and the resulting cell pellet is suspended in medium. Finally, the cells are seeded in a culture vessel and cultured in a medium with a CO 2 concentration of 3% or more and 5% or less and a confluence rate of 95% or less.
• a cell exfoliation means such as trypsin and exfoliated from the culture vessel.
• the resulting cell suspension is then centrifuged, the supernatant is removed, and the resulting cell pellet is suspended in medium.
• the cells are seeded in a culture vessel and cultured in a medium with a CO 2 concentration of 3% or more and 5% or less and a confluence rate of 95% or less.
• the culture period of the above culture may be, for example, 2 to 21 days, more preferably 3 to 19 days, still more preferably 4 to 17 days.
• cells that have been passaged n times can be obtained by repeating passage and culture (n indicates an integer of 1 or more).
• the lower limit of the number of passages n is, for example, once or more, preferably 2 times or more, more preferably 3 times or more, still more preferably 4 times or more, still more preferably 5 times or more, from the viewpoint of mass production of cells. be.
• the upper limit of the number of passages n is preferably 25 times or less, 20 times or less, 15 times or less, 10 times or less, for example, from the viewpoint of suppressing cell aging.
• a cell exfoliating agent may be used.
• trypsin As the above-mentioned cell exfoliating means, for example, a cell exfoliating agent may be used.
• trypsin As the cell exfoliating agent, trypsin, collagenase, dispase, ethylenediaminetetraacetic acid (EDTA) and the like can be used, but the cell stripping agent is not particularly limited.
• EDTA ethylenediaminetetraacetic acid
• the cell stripping agent is not particularly limited.
• a commercially available cell exfoliating agent may be used. For example, trypsin-EDTA solution (manufactured by Thermo Fisher Scientific), TrypLE Select (manufactured by Thermo Fisher Scientific), Accutase (manufactured by Thermo Fisher Scientific), Accutase (manufactured by Stemcell Technologys), Acculex, etc.
• a physical cell detachment means may be used, and for example, a cell scraper (manufactured by Corning Inc.) can be used, but the present invention is not limited thereto.
• the cell ablation means may be used alone or in combination of two or more.
• the means for cryopreserving a cell population containing adherent cells such as mesenchymal stem cells in the present invention is not particularly limited, and examples thereof include a program freezer, a deep freezer, and storage in liquid nitrogen.
• the freezing temperature is preferably -30 ° C or lower, -40 ° C or lower, -50 ° C or lower, -80 ° C or lower, -90 ° C or lower, -100 ° C or lower, -150 ° C or lower. , -180 ° C or lower, or -196 ° C (liquid nitrogen temperature) or lower.
• the preferred freezing speeds for freezing are, for example, -1 ° C / min or less, -2 ° C / min or less, -5 ° C / min or less, -9 ° C / min or less, -10 ° C / min or less. Minutes or less, -11 ° C / minute or less, or -15 ° C / minute or less.
• a program freezer is used as the above freezing means, for example, at a freezing rate of -2 ° C./min or more and -1 ° C./min or less, up to a temperature between -50 ° C. and -30 ° C. (for example, -40 ° C.).
• a freezing rate of -11 ° C / min or higher and -9 ° C / min or lower for example, -10 ° C / min.
• the temperature can be rapidly lowered to -196 ° C. for freezing, and then cryopreservation can be performed in liquid nitrogen (gas phase). It can also be stored in liquid nitrogen (liquid phase).
• the above cell population may be frozen in an arbitrary storage container.
• the storage container include, but are not limited to, a cryotube, a cryovial, a freezing bag, and an infusion bag.
• the above cell population may be frozen in any cryopreservation solution.
• a cryopreservation solution a commercially available cryopreservation solution may be used.
• CP-1 registered trademark
• BAMBANKER manufactured by Lymphotech
• STEM-CELLBANKER manufactured by Nippon Zenyaku Kogyo Co., Ltd.
• ReproCryo RM manufactured by Reprocell
• CryoNovo Acron Biotechnology
• cryopreservation solution manufactured by Biomagnetic Industries
• CryoStor manufactured by HemaCare
• the cryopreservation solution may be used alone or in combination of two or more.
• the above cryopreservation solution can contain a predetermined concentration of polysaccharides.
• the preferable concentration of the polysaccharide is, for example, 1% by mass or more, 2% by mass or more, 4% by mass or more, or 6% by mass or more.
• the preferable concentration of the polysaccharide is, for example, 20% by mass or less, 18% by mass or less, 16% by mass or less, 14% by mass or less, or 13% by mass or less.
• Examples of the polysaccharide include, but are not limited to, hydroxylethyl starch (HES) and dextran (Dextran40, etc.).
• HES hydroxylethyl starch
• Dextran40 dextran
• the above cryopreservation solution can contain a predetermined concentration of dimethyl sulfoxide (DMSO).
• DMSO dimethyl sulfoxide
• the preferred concentration of DMSO is, for example, 1% by mass or more, 2% by mass or more, 3% by mass or more, 4% by mass or more, or 5% by mass or more.
• the preferable concentration of DMSO is, for example, 20% by mass or less, 18% by mass or less, 16% by mass or less, 14% by mass or less, 12% by mass or less, or 10% by mass or less.
• the above cryopreservation solution may contain albumin having a predetermined concentration higher than 0% by mass.
• the preferable concentration of albumin is, for example, 1% by mass or more, 2% by mass or more, 3% by mass or more, or 4% by mass or more.
• the preferable concentration of albumin is, for example, 30% by mass or less, 20% by mass or less, 10% by mass or less, or 9% by mass or less.
• Examples of albumin include, but are not limited to, bovine serum albumin (BSA), mouse albumin, human albumin and the like.
• the cell population containing the mesenchymal stem cells provided by the present invention satisfies that the ratio of mesenchymal stem cells positive for CD73, CD90, and CD105 is 80% or more. You may.
• CD73 means a differentiation cluster 73 and is a protein also known as 5-nucleotidase or Ecto-5'-nucleotidase.
• CD90 means differentiation cluster 90 and is a protein also known as Thy-1.
• CD105 means differentiation cluster 105 and is a protein also known as Endoglin.
• the proportion of mesenchymal stem cells positive for CD73 in the cell population is 80% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92%. It may be 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%.
• the proportion of mesenchymal stem cells positive for CD90 in the cell population is 80% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92%. It may be 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%.
• the proportion of mesenchymal stem cells positive for CD105 in the cell population is 80% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92%. It may be 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%.
• the cell population containing the mesenchymal stem cells provided by the present invention satisfies that the ratio of mesenchymal stem cells exhibiting negative for CD45 and CD31 is 80% or more. good.
• CD45 means a differentiation cluster 45, and is a protein also known as PTPRC (Protein tyrosine phosphatase, receptor type, C) or LCA (Leukocyte common engine).
• PTPRC Protein tyrosine phosphatase, receptor type, C
• LCA Leukocyte common engine
• CD31 means a differentiation cluster 31, and is a protein also known as Hematopoietic progenitor cell antigen CD31.
• the proportion of mesenchymal stem cells that are negative for CD45 in the cell population is 80% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92%. It may be 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%.
• the proportion of mesenchymal stem cells that are negative for CD31 in the cell population is 80% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92%. It may be 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%.
• the compressive stress of the medium for transporting and storing the excised fat was as follows: 2 mL of the medium was placed in a 24-well plate, the medium was compressed with a plunger having a diameter of 1 cm at 4 ° C, and the medium was compressed by 1.5 mm. The stress at this time (unit is N) was measured by EZ-TEST (Shimadzu Corporation, EZ-SX).
• ⁇ Comparative Example 1 Examination of adipose tissue transport> (Process 1: Collection, transport and storage of excised fat)
• the abdomen of the donor (donor A) who gave informed consent was incised with a scalpel with a sharp edge, and the fat was excised with mosquito forceps and tweezers.
• the weight of the excised fat collected was weighed, and 0.06 g of the excised fat was placed in a 1.5 mL microtube as it was, and transported and stored in a refrigerated (4 ° C.) environment for about 20 hours.
• the cell concentration was measured using a Nucleocounter (model: NC-100) manufactured by ChemoMetec.
• NC-100 manufactured by ChemoMetec.
• the concentration of dead cells in this measurement was measured by sucking the cell suspension into a cassette (model number: 941-0002) containing a PI solution for staining dead cells.
• the total cell concentration in this measurement is determined by mixing the cell suspension with the cell treatment reagent A100 (model number: 910-0003) and the cell treatment reagent B (model number: 910-0002) in equal amounts to control all cells.
• the PI solution was targeted for staining, and the cells were sucked into the above-mentioned cassette and measured.
• the cell number and the survival rate of the obtained fat-derived MSC were calculated.
• the fat-derived MSC could not be produced by the method of Comparative Example 1.
• ⁇ Comparative Example 2 Examination of adipose tissue transport> (Process 1: Collection, transport and storage of excised fat) 0.06 g of excised fat collected from a donor (donor B) different from the donor in Comparative Example 1 containing 1 mL of a Hanks balanced salt solution (without Ca / Mg) (compressive stress of the medium is 0.00 N) 1
• the excised fat was transported and stored in the same manner as in Process 1 of Comparative Example 1, except that it was housed in a 5.5 mL microtube.
• ⁇ Example 1 Examination of adipose tissue transport> (Process 1: Collection, transport and storage of excised fat) 0.06 g of excised fat collected from the same donor (donor B) as the donor in Comparative Example 2 was placed in a 1.5 mL microtube, and a gelatin-containing Hanks balanced salt solution (Ca. Excised fat was transported and stored by the same method as in Process 1 of Comparative Example 1 except that it was embedded in 1 mL (without Mg). For embedding of the excised fat, a method was used in which the prepared gelatin-containing Hanks balanced salt solution was liquefied at 37 ° C., the excised fat was placed in the solution, and then solidified at 4 ° C. Then, it was transported and stored in a refrigerator (4 ° C.) for 20 hours, heated to 37 ° C. to liquefy the gelatin-containing Hanks balanced salt solution, and the excised fat was taken out to carry out Process 2.
• Process 1 Collection, transport and storage of exc
• the number of cells in the 0th passage cell population derived from Donor B of Example 1 was 3.0 ⁇ 105, and the survival rate was 95.9%. From the above, it was found that in the method of Example 1, many adhesive cells could be confirmed in the culture vessel, and many fat-derived MSCs having a high survival rate could be produced.
• the cell population of the first passage was exfoliated using TripLE Select when it reached the subconfluent, diluted with a medium, and recovered by centrifugation.
• the surface antigen analysis was performed using a Guava easyCyte Single manufactured by MERCK, with the number of analyzed cells: 10,000 cells and the flow rate setting: Slow.
• antibodies for isotype control PE Mouse IgG1 k Isotype Control (BD company / model number: 555749), FITC Mouse IgG1 k Isotype Control (BD company / model number: 555748) and AlexaFluor647 (BD company / model number: 557714) was used as an antibody against the CD73 antigen, PE Mouse Anti-Human CD73 (manufactured by BD company / model number: 550257), and PE Mouse Anti-Human CD90 (manufactured by BD company) as an antibody against the CD90 antigen.
• the positive rates of CD73, CD90, and CD105 were all 90% or more (specifically, CD73: 100%, The positive rate of CD90: 100%, CD105: 100%), CD45, and CD31 was less than 5% (negative rate was 95% or more) (specifically, the positive rate of CD45: 1% (negative rate: 99%). ), CD31 positive rate: 1% (negative rate: 99%)). From the above results, it was confirmed that the cell population of the first passage of Example 1 was a cell population containing high-purity mesenchymal stem cells.
• Example 2 In Example 2 and Comparative Example 3 below, the same donor C excised fat was used.
• Example 2 Examination of adipose tissue transport> (Process 1: Collection, transport and storage of excised fat)
• a gelatin-containing Hanks balanced salt having a compressive stress of 1.09 N was placed in a 1.5 mL microtube containing 0.15 g of agarose collected from a donor (donor C) different from the donors in Comparative Examples 1 and 2. It was embedded in a solution (without Ca / Mg) (donor C-gelatin), and the other was embedded with 1 mL of an agarose-containing Hanks balanced salt solution (without Ca / Mg) having a compressive stress of 1.71 N (without Ca / Mg).
• the excised fat was transported and stored in the same manner as in Process 1 of Comparative Example 1.
• the prepared agarose-containing Hanks equilibrium salt solution was solidified at room temperature or lower, and the excised fat was embedded in a finely crushed gel. Then, it was transported and stored in a refrigerator (4 ° C.) for 20 hours, the excised fat was removed from the gel, and the process 2 was carried out.
• the number of cells in the 0th passage cell population derived from the donor C-gelatin of Example 2 was 1.0 ⁇ 106 , and the survival rate was 96.8%.
• the number of cells in the 0th passage cell population derived from the donor C-agarose of Example 2 was 1.5 ⁇ 106 , and the survival rate was 98.6%. From the above, it was found that in the method of Example 2, many adhesive cells could be confirmed in the culture vessel, and many fat-derived MSCs having a high survival rate could be produced.
• the number of cells in the 0th passage cell population derived from Donor C of Comparative Example 3 was 0.1 ⁇ 106 , the survival rate was 90.8%, and the donor C of Example 2 was used. -Only 1/10 or less of the cell population of the 0th passage derived from gelatin and donor C-agarose could be obtained, and the survival rate was also slightly low. From the above, it was found that the method of Comparative Example 3 was not suitable for producing a fat-derived MSC.
• Example 3 Examination of adipose tissue transport> (Process 1: Collection, transportation and storage of sucked fat) 1 mL of suction fat (donor D-suction) collected by liposuction from a donor (donor D) different from the donors in Examples 1 and 2 was placed in a 1.5 mL microtube, and each gelatin having a compressive stress shown in Table 2 was placed. It was embedded in 1 mL of a Hanks equilibrium salt solution (without Ca / Mg) and transported and stored in a refrigerated (4 ° C.) environment for about 72 hours.
• a Hanks equilibrium salt solution without Ca / Mg
• Process 3 Culture of fat-derived MSC
• Cells of the 0th passage were seeded in the same manner as in Process 3 of Comparative Example 1 except that each SVF obtained from donor D-suction was seeded in a T-25 flask (manufactured by Corning Inc.) in a culture vessel. Populations were obtained and adherent cells were collected.
• the number of cells in the 0th passage cell population derived from the donor D-suction (1) of Example 3 was 1.0 ⁇ 106 , and the survival rate was 97.4%, and the donor of Example 3 was obtained.
• the number of cells in the 0th passage cell population derived from D-suction (2) was 1.6 ⁇ 106 , and the survival rate was 98.1%, which was derived from the donor D-suction (3) of Example 3.
• the number of cells in the 0th passage cell population was 1.9 ⁇ 10 6 , and the survival rate was 98.8%.
• the number of cells was 0.8 ⁇ 106 , and the survival rate was 97.1%. From the above, it was found that in the method of Example 3, many adhesive cells could be confirmed in the culture vessel, and many fat-derived MSCs having a high survival rate could be produced.
• ⁇ Comparative Example 4 Examination of Adipose Tissue Transport> (Process 1: Collection, transportation and storage of sucked fat) 1 mL of suction fat (donor D-suction) collected by liposuction from the same donor (donor D) as the donor in Example 3 was mixed with a Hanks balanced salt solution (without Ca / Mg) (the compressive stress of the medium was 0. 00N) The sucked fat was transported and stored in the same manner as in Process 1 of Example 3 except that it was housed in a 1.5 mL microtube containing 1 mL.
• Example 4 Examination of adipose tissue transport> (Process 1: Collection, transportation and storage of sucked fat) 1 mL of suction fat (donor D-suction) collected by suction fat from the same donor (donor D) as the donor in Example 3 is housed in a 1.5 mL microtube, and the fibrin having a compressive stress of 6.86 N is contained in the medium. (Product name: Borheel) The aspirated fat was transported and stored by the same method as in Process 1 of Example 3 except that it was embedded in 1 mL.
• ⁇ Comparative Example 5 Examination of adipose tissue transport> (Process 1: Collection, transportation and storage of sucked fat) 1 mL of suction fat (donor D-suction) collected by liposuction from the same donor (donor D) as the donor in Example 3 is housed in a 1.5 mL microtube, and the compressive stress of the medium is 12.27 N. The sucked fat was transported and stored by the same method as in Process 1 of Example 3 except that it was embedded in 1 mL of a Hanks balanced salt solution (without Ca / Mg).
• Example 5 Examination of adipose tissue transport> (Process 1: Collection, transportation and storage of sucked fat)
• the aspirated fat is transported by the same method as in Process 1 of Example 3 except that the conditions for transporting and storing the collected aspirated fat (donor D-suction) are about 192 hours in a refrigerated (4 ° C.) environment. And saved.
• Example 5 As a result, after culturing for 7 days, the number of cells in the 0th passage cell population derived from the donor D-suction of Example 5 was 1.5 ⁇ 105, and the survival rate was 96.3%. From the above, it was found that in the method of Example 5, many adhesive cells could be confirmed in the culture vessel, and many fat-derived MSCs having a high survival rate could be produced.
• ⁇ Comparative Example 6 Examination of adipose tissue transport> (Process 1: Collection, transportation and storage of sucked fat)
• the aspirated fat is transported by the same method as in Process 1 of Comparative Example 4, except that the conditions for transporting and storing the collected aspirated fat (donor D-suction) are about 192 hours in a refrigerated (4 ° C.) environment. And saved.
• Table 3 shows the cell numbers and viability of the 0th passage cell populations of Examples 3, 4, and 5 and Comparative Examples 4, 5, and 6.
• Example 6 In Example 6 and Comparative Example 7, the same donor D excised fat was used.
• ⁇ Example 6 Examination of adipose tissue transport> (Process 1: Collection, transport and storage of excised fat) A gelatin-containing Hanks having a compressive stress of 1.09 N in a 1.5 mL microtube containing 0.1 g of excised fat (donor D-excision) collected from a donor (donor D) different from that of the donor in Comparative Example 1. The excised fat was transported and stored by the same method as in Process 1 of Comparative Example 1 except that it was embedded in 1 mL of a balanced salt solution (without Ca / Mg).
• Example 6 As a result, after culturing for 16 days, the number of cells in the 0th passage cell population derived from the donor D-resect of Example 6 was 5.0 ⁇ 105, and the survival rate was 98.3%. From the above, it was found that in the method of Example 6, many adhesive cells could be confirmed in the culture vessel, and many fat-derived MSCs having a high survival rate could be produced.
• ⁇ Comparative Example 7 Examination of adipose tissue transport> (Process 1: Collection, transport and storage of excised fat) Excised fat was removed by the same method as in Process 1 of Comparative Example 1 except that 0.1 g of excised fat (donor D-excision) collected from a donor (donor D) different from that of the donor in Comparative Example 1 was used. Transported and stored.
• Table 4 shows the number of cells and the survival rate of the 0th passage cell populations of Example 6 and Comparative Example 7.
• Examples 7 and 8 and Comparative Example 8 used the same donor E amnion tissue.
• Example 7 Examination of amniotic membrane tissue transport> (Process 1: Amniotic membrane collection, transportation and storage) Fetal membranes and placenta, which are fetal appendages, were aseptically collected from a pregnant woman (donor E) who gave informed consent to a case of selective caesarean section. The obtained fetal membrane and placenta were placed in a container containing physiological saline, and the amniotic membrane was detached from the stump of the fetal membrane. The amniotic membrane was washed with a Hanks balanced salt solution (without Ca / Mg).
• the weight of the collected amniotic membrane was measured, and 1 g of amniotic membrane was embedded in 1 mL of a gelatin-containing Hanks balanced salt solution (without Ca / Mg) having a compressive stress of 1.09 N and contained in a 1.5 mL microtube.
• a method was used in which the prepared gelatin-containing Hanks balanced salt solution was liquefied at 37 ° C., the amniotic membrane was placed in the solution, and then the amniotic membrane was solidified at 4 ° C. Then, after transporting and storing in a refrigerator (4 ° C.) for about 216 hours, the mixture was heated to 37 ° C. to liquefy the gelatin-containing Hanks balanced salt solution, and the amniotic membrane was taken out to carry out Process 2.
• Example 7 As a result, after culturing for 12 days, the number of cells in the 0th passage cell population derived from Donor E of Example 7 was 9.5 ⁇ 105, and the survival rate was 98.6%. From the above, it was found that in the method of Example 7, many adhesive cells could be confirmed in the culture vessel, and many amniotic membrane-derived MSCs having a high survival rate could be produced.
• ⁇ Comparative Example 8 Examination of amniotic tissue transport> (Process 1: Amniotic membrane collection, transportation and storage) 1 g of amniotic membrane collected from the same donor (donor E) as the donor in Example 7 is contained in a 1.5 mL microtube containing 1 mL of a Hanks balanced salt solution (without Ca / Mg) (compressive stress of the medium is 0.00 N). The amniotic membrane was transported and stored in the same manner as in Process 1 of Example 7, except that it was housed in.
• Example 8 Examination of amniotic tissue transport> (Process 1: Amniotic membrane collection, transportation and storage) 1 g of amniotic membrane collected from the same donor (donor E) as the donor in Example 7 by the same method as in Process 1 of Example 7, was obtained from a gelatin-containing Hanks balanced salt solution having a compressive stress of 1.09 N as a medium. It was embedded in 1 mL (without Ca / Mg) and contained in a 1.5 mL microtube.
• the amniotic membrane For the embedding of the amniotic membrane, a method was used in which the prepared gelatin-containing Hanks balanced salt solution was liquefied at 37 ° C., the amniotic membrane was placed in the solution, and then the amniotic membrane was solidified at 4 ° C. Then, it was transported and stored at room temperature (about 20 ° C.) for about 110 hours, heated to 37 ° C. to liquefy the gelatin-containing Hanks balanced salt solution, and the amniotic membrane was taken out to carry out Process 2.
• Example 6 As a result, after culturing for 11 days, the number of cells in the 0th passage cell population derived from Donor E of Example 8 was 1.3 ⁇ 106 , and the survival rate was 98.3%. From the above, it was found that in the method of Example 6, many adhesive cells could be confirmed in the culture vessel, and many amniotic membrane-derived MSCs having a high survival rate could be produced.
• Table 5 shows the cell numbers and viability of the 0th passage cell populations of Examples 7 and 8 and Comparative Example 8.
• amniotic membrane MSCs with high survival rate can be produced by storing and / or transporting the amniotic membrane tissue in a medium having a compressive stress greater than 0 N and 12 N or less in a state of being embedded.
• Tissues containing adhesive cells are stored and / or transported in a state of being embedded in a medium having a compressive stress greater than 0 and 12 N or less.
• the tissue embedded in the medium is taken out from the medium and the adhesive cells are separated. That is, according to the present invention, the tissue containing the adhesive cells such as mesenchymal stem cells is safely stored / transported. This makes it possible to efficiently produce adherent cells from raw material tissues containing adherent cells after storage / transport. This can be expected to expand opportunities for providing treatment to patients, reduce the burden on cell cultures, and reduce manufacturing costs and medical costs.

Landscapes

• Engineering & Computer Science (AREA)
• Health & Medical Sciences (AREA)
• Biomedical Technology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Biotechnology (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Cell Biology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=80355347

Family Applications (1)

Country Status (2)

Cited By (1)

Citations (4)

• 2021
  • 2021-08-25 JP JP2022545675A patent/JPWO2022045201A1/ja active Pending
  • 2021-08-25 WO PCT/JP2021/031187 patent/WO2022045201A1/ja active Application Filing

Patent Citations (4)

Also Published As

Similar Documents

Legal Events